Cochlear record revenue fails to impress investors
Sometimes you just can’t win. After posting a record revenue of $391.7 million – all the more impressive at a time of the high Aussie dollar – the stock market has turned its back on Cochlear, driving its share price down by over 9% in today’s trading.
The record revenue comes a year after Cochlear posted a $20.4 million loss, hampered by its costly $138.8m product recall of the CI500 implant.
Yet strong sales over the past financial year have almost gone a long way to recouping the cost of the recall, with net profit after tax of $77.7 million.
The company also announced a dividend of $1.25 per share (40% franked), up 4%.
“This is a pleasing result,” said Cochlear CEO, Dr Chris Roberts. “Yet again, a record number of recipients received one of our implants.”
However, investors were less impressed by the results - perhaps responding to some analyst expectations of even greater sales - and sold off Cochlear stock in relatively heavy trading throughout the day, ultimately shedding $7.50 to $72.96 at market close.
Reproductive impacts of PFAS exposure revealed
New studies have found that PFAS exposure can significantly alter male reproductive health, and...
'Longevity gene' could reverse damage from rapid aging disease
A gene found in supercentenarians, who live exceptionally long lives, could counteract the...
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
